• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Does Guanfacine Affect Tic Severity in Children With Chronic Tic Disorders?

Does Guanfacine Affect Tic Severity in Children With Chronic Tic Disorders?

November 1, 2017
Arian Ayon Verduzco, Pharm.D candidate (2018)
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Arian Ayon Verduzco, Pharm.D candidate (2018) Ms. Verduzco has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review Of: Murphy TK et al, J Child Adolesc Psychopharmacol 2017;20(20):1–9

Tic disorders, including Tourette’s, often co-occur with ADHD, OCD, and anxiety disorders. Guanfacine is often tried for all of these conditions. Randomized placebo-controlled trials of immediate release guanfacine have been mixed, with one showing 31% improvement in tics but another showing no significant improvement. Extended release (ER) guanfacine, while indicated for ADHD, has not been studied in children with tic disorders. Murphy et al set out to investigate its safety and efficacy as a treatment for chronic tic disorder (CTD).

This 8-week, double-blind, placebo-controlled trial included 34 subjects aged 6–17 years (mean 11 years), who met criteria for CTD. Children were either medication-free or on a stable OCD or anxiety regimen for at least 8 weeks. Participants were randomly assigned to either guanfacine ER (n = 16) or placebo (n = 18). Those in the medication group received a starting dose of 1 mg in the morning, which could be increased to as much as 4 mg per day and divided into two doses at the clinician’s discretion. Mean guanfacine ER dose was 2.6 mg. The primary outcome was change from baseline in the Yale Global Tic Severity Scale (YGTSS).

At 8 weeks, both groups had a few positive responders on the YGTSS; however, there was no significant difference between guanfacine ER (19%; 3/16) and placebo (22%; 4/18). Parent ratings of tic severity in the guanfacine group showed improvement, whereas no effect was seen with placebo. In addition, only the guanfacine group showed an improvement in ADHD symptoms. Common side effects in patients on guanfacine included fatigue, drowsiness, dry mouth, headache, irritability, stomachache, and decreased appetite.

CCPR’s Take
In this small pilot study, guanfacine ER was no more effective than placebo for improving symptoms in children with CTD. On the other hand, it did not worsen tics, which is reassuring, especially since stimulants can aggravate tics when used for ADHD. Guanfacine may have a place in treating ADHD specifically for children with tic disorder, with the modest goal of easing ADHD symptoms while at least not worsening tics.
Child Psychiatry
KEYWORDS ocd research_updates
Arian Ayon Verduzco, Pharm.D candidate (2018)

More from this author
www.thecarlatreport.com
Issue Date: November 1, 2017
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Adolescents, CCPR, November/December 2017
Does Guanfacine Affect Tic Severity in Children With Chronic Tic Disorders?
Does Methylphenidate Use in Children and Young Adults Increase Risk of Suicide?
Tips on Managing Medications With Adolescents
Understanding Risk-Taking in Adolescents
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.